We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Janssen-Cilag Ltd

50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG, UK
Telephone: +44 1494 567 567
Fax: +44 1494 567 568
Medical Information Direct Line: +353 1 800 709 122
Medical Information e-mail: medinfo@janssen-cilag.co.uk
Customer Care direct line: +353 1 620 2300
Medical Information Facsimile: +44 (0) 1494 567 445


Summary of Product Characteristics last updated on medicines.ie: 19/06/2017
SPC Sublimaze 50 micrograms/ml, Solution for Injection


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Sublimaze 50 micrograms/ml, Solution for Injection.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1 ml of solution contains 78.5 micrograms fentanyl citrate equivalent to 50 micrograms fentanyl base.

Ampoule of 2ml contains 100 micrograms of fentanyl.

Ampoule of 10ml contains 500 micrograms of fentanyl.

Excipient(s) with known effect:

Sodium 3.5 mg/ml.

For a full list of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Solution for injection. (Injection)


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

As an adjunct in the maintenance of general anaesthesia and analgesia.

In conjunction with a neuroleptic agent in the technique of neuroleptanalgesia.

As a respiratory depressant/analgesic in patients requiring prolonged assisted ventilation.

As the sole intravenous anaesthetic agent in surgical procedures.


Go to top of the page
4.2 Posology and method of administration

Fentanyl should be given only in an environment where the airway can be controlled and by personnel who can control the airway (see section 4.4 Special warnings and precautions).

The dosage of fentanyl should be individualised according to age, body weight, physical status, underlying pathological condition, use of other drugs, and type of surgery and anaesthesia.

Techniques that involve analgesia in a spontaneously breathing child should only be used as part of an anaesthetic technique, or given as part of a sedation/ analgesia technique, with experienced personnel in an environment that can manage sudden chest wall rigidity requiring intubation, or apnoea requiring airway support (see section 4.4).

It is recommended to wear gloves while opening the ampoule (see section 6.6 Special precautions for disposal and other handling).

Method of administration:

For intravenous administration.

Posology:

As an adjunct in the maintenance of general anaesthesia and analgesia

Adults:

For both balanced anaesthesia and total intravenous anaesthesia (TIVA), dose amounts and the intervals between doses should be adjusted to account for the duration and severity of the surgical procedure.

Bolus administration

0.0005-0.01 mg/kg

Continuous infusion

0.0005-0.005 mg/kg/h

Children:

0.001 mg/kg supplements as necessary.

In conjunction with a neuroleptic agent in the technique of neuroleptanalgesia

Adults:

The usual dose is 0.1 mg initially, with maintenance doses of 0.05 mg as necessary.

In patients requiring prolonged assisted ventilation

Adults:

Up to 0.6 mg initially, with supplemental doses of 0.05 mg to 0.2 mg.

Children:

0.001 mg/kg supplements as necessary.

As sole IV anaesthetic agent in surgical procedures

Adults:

The usual dose is 0.1 mg to 0.8 mg initially, depending on response, with maintenance doses of 0.05 mg as necessary, in conjunction with controlled ventilation.

Children:

The usual dose is 0.01 mg/kg initially, depending on response, with maintenance doses of 0.001 mg/kg as necessary, in conjunction with controlled ventilation.

Elderly and debilitated patients:

As with other opioids, the initial dose should be reduced in the elderly (>65 years of age) and in debilitated patients. The effect of the initial dose should be taken into account in determining supplemental doses.

Obese patients:

In obese patients there is a risk of overdosing if the dose is calculated based on body weight. Obese patients should have dosage calculated according to their estimated lean body mass.

Renal Impairment

In patients with renal impairment reduced dosing of Sublimaze should be considered and these patients should be observed carefully for signs of fentanyl toxicity (see section 5.2 Pharmacokinetic properties).


Go to top of the page
4.3 Contraindications

Hypersensitivity (or idiosyncratic response) to the active substance or to any of the excipients listed in section 6.1 or other opioids.

Respiratory depression, cyanosis, excessive bronchial exudation, bronchoconstriction (reversible or irreversible) or chronic pulmonary disease.

After operative interventions in the biliary tract.

Use in patients who are receiving, or have within two weeks received, monoamine oxidase inhibitors.


Go to top of the page
4.4 Special warnings and precautions for use

Sublimaze is intended for use in hospitals only by those trained in anaesthesia and familiar with the use of potent opioids when given intravenously.

Sublimaze should be given only in an environment where the airway can be controlled and by personnel who can control the airway.

Respiratory depression

As with all potent opioids, respiratory depression is dose-related and can be reversed by a specific opioid antagonist, but additional doses may be necessary because the respiratory depression may last longer than the duration of action of the opioid antagonist. Profound analgesia is accompanied by marked respiratory depression, which can persist or recur in the post-operative period. Therefore, patients should remain under appropriate surveillance. Resuscitation equipment and opioid antagonists should be readily available. Hyperventilation during anaesthesia may alter the patient's responses to CO2, thus affecting respiration post-operatively.

Muscle rigidity

Induction of muscle rigidity, which may also involve the thoracic muscles, can occur, but can be avoided by the following measures: slow IV injection (ordinarily sufficient for lower doses), premedication with benzodiazepines and the use of muscle relaxants.

Non-epileptic (myo) clonic movements can occur.

Cardiac disease

Bradycardia and possibly cardiac arrest can occur if the patient has received an insufficient amount of anticholinergic, or when fentanyl is combined with non-vagolytic muscle relaxants. Bradycardia can be treated with atropine.

Opioids may induce hypotension, especially in hypovolaemic patients. Appropriate measures to maintain a stable arterial pressure should be taken.

Dependence and abuse

Dependence on fentanyl, when given as a single dose or finite number of intra-operative doses has not been reported. However, repeated administration at short term intervals for prolonged periods may result in the development of dependence, with a withdrawal syndrome on cessation of therapy.

Fentanyl can be abused in a manner similar to other opioid agonists.

Special dosing conditions

The use of rapid bolus injections of opioids should be avoided in patients with compromised intracerebral compliance; in such patients the transient decrease in mean arterial pressure has occasionally been accompanied by a short-lasting reduction of the cerebral perfusion pressure.

This product should only be used with great caution in patients who are dependent on drugs in view of the severe respiratory depression which may ensue. Patients on chronic opioid therapy or with history of opioid abuse may require higher doses.

It is recommended to reduce the dosage in the elderly and in debilitated patients.

Opioids should be titrated with caution in patients with any of the following conditions: uncontrolled hypothyroidism; pulmonary disease, decreased respiratory reserve; alcoholism; impaired hepatic or renal function. Such patients also require prolonged post-operative monitoring.

Repeated use will result in the development of tolerance requiring increases in dosage to achieve the required effects. Generally it is preferable to vary the opioid analgesics at intervals in patients requiring prolonged periods of analgesia.

Interaction with neuroleptics

If fentanyl is administered with a neuroleptic, the user should be familiar with the special properties of each drug, particularly the difference in duration of action. When such a combination is used, there is a higher incidence of hypotension. Neuroleptics can induce extrapyramidal symptoms that can be controlled with anti-Parkinson agents.

Bile duct

As with other opioids, due to the anti-cholinergic effects, administration of fentanyl may lead to increases of bile duct pressure and, in isolated cases, spasms of the Sphincter of Oddi might be observed.

Myasthenia gravis

In patients with myasthenia gravis, careful consideration should be applied in the use of certain anticholinergic agents and neuromuscular-blocking pharmaceutical agents prior to, and during, the administration of a general anaesthetic regimen which includes administering intravenous fentanyl.

Serotonin syndrome

Caution is advised when fentanyl is coadministered with drugs that affect the serotonergic neurotransmitter systems.

The development of a potentially life-threatening serotonin syndrome may occur with the concomitant use of serotonergic drugs such as Selective Serotonin Re-uptake Inhibitors (SSRIs) and Serotonin Norepinephrine Re-uptake Inhibitors (SNRIs), and with drugs which impair metabolism of serotonin (including Monoamine Oxidase Inhibitors [MAOIs]). This may occur within the recommended dose.

Serotonin syndrome may include mental-status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g. tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (e.g., hyper-reflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea).

If serotonin syndrome is suspected, rapid discontinuation of fentanyl should be considered.

Paediatric population

Techniques that involve analgesia in a spontaneously breathing child should only be used as part of an anaesthetic technique, or given as part of a sedation/ analgesia technique, with experienced personnel in an environment that can manage sudden chest wall rigidity requiring intubation, or apnoea requiring airway support.

Sublimaze contains 3.5 mg sodium per ml. To be taken into consideration by patients on a controlled sodium diet.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Effect of other drugs on fentanyl

Central Nervous System (CNS) depressants

Drugs such as barbiturates, benzodiazepines, neuroleptics, general anaesthetics and other, non-selective CNS depressants (e.g., alcohol) may potentiate the respiratory depression of opioids.

When patients have received such drugs, the dose of fentanyl required may be less than usual. Concomitant use with Sublimaze in spontaneously breathing patients may increase the risk of respiratory depression, profound sedation, coma, and death.

Cytochrome P450 3A4 (CYP3A4) inhibitors

Fentanyl, a high clearance drug, is rapidly and extensively metabolised mainly by CYP3A4. When Sublimaze is used, the concomitant use of a CYP3A4 inhibitor may result in a decrease in fentanyl clearance. With single-dose Sublimaze administration, the period of risk for respiratory depression may be prolonged, which may require special patient care and longer observation. With multiple-dose Sublimaze administration, the risk for acute and/or delayed respiratory depression may be increased, and a dose reduction of Sublimaze may be required to avoid accumulation of fentanyl. Oral ritonavir (a potent CYP3A4 inhibitor) reduced the clearance of a single intravenous Sublimaze dose by two thirds, although peak plasma concentrations of fentanyl were not affected. However, itraconazole (another potent CYP3A4 inhibitor) at 200 mg/day given orally for 4 days had no significant effect on the pharmacokinetics of a single intravenous Sublimaze dose. Co-administration of other potent or less potent CYP3A4 inhibitors, such as voriconazole or fluconazole, and Sublimaze may also result in an increased and/or prolonged exposure to fentanyl.

Pretreatment with, or concurrent administration of, cimetidine may increase plasma levels of fentanyl, when repeated doses of both drugs are used.

Bradycardia may be intensified by pretreatment with, or concurrent use of, drugs such as beta-blockers, suxamethonium, halothane, vecuronium, which may themselves cause bradycardia.

Serotonergic Drugs

Coadministration of fentanyl with a serotonergic agent, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening condition (see section 4.3 Contraindications).

Effect of fentanyl on other drugs

Following the administration of fentanyl, the dose of other CNS depressant drugs should be reduced. This is particularly important after surgery, because profound analgesia is accompanied by marked respiratory depression, which can persist or recur in the postoperative period. Administration of a CNS depressant, such as a benzodiazepine, during this period may disproportionally increase the risk for respiratory depression.

Plasma concentrations of etomidate increased considerably (by a factor of 2-3) when combined with fentanyl. The total plasma clearance and volume of distribution of etomidate is decreased by a factor 2 to 3 without a change in half-life when administered with fentanyl.

Simultaneous administration of fentanyl and intravenous midazolam results in an increase in the terminal plasma half-life and a reduction in the plasma clearance of midazolam. When these drugs are co-administered with fentanyl their dose may need to be reduced.


4.6 Fertility, pregnancy and lactation

Pregnancy

There are no adequate data from the use of fentanyl in pregnant women. Fentanyl can cross the placenta in early pregnancy. Studies in animals have shown some reproductive toxicity (see Section 5.3, Preclinical safety data). The potential risk for humans is unknown.

Administration during childbirth (including Caesarean section) is not recommended because fentanyl crosses the placenta and may suppress spontaneous respiration in the newborn period. If fentanyl is administered, assisted ventilation equipment must be immediately available for the mother and infant if required. An opioid antagonist for the child must always be available.

Breast-feeding

Fentanyl is excreted into human milk. Therefore, breast feeding or use of expressed breast milk is not recommended for 24 hours following the administration of the drug. The risk/benefit of breastfeeding following fentanyl administration should be considered.

Fertility

There are no clinical data on the effects of fentanyl on male or female fertility. In animal studies, some tests on rats showed reduced female fertility at maternal toxic doses (see section 5.3 Preclinical data).


Go to top of the page
4.7 Effects on ability to drive and use machines

Where early discharge is envisaged, patients should be advised not to drive or operate machinery for at least 24 hours following administration.


Go to top of the page
4.8 Undesirable effects

The safety of fentanyl IV was evaluated in 376 subjects who participated in 20 clinical trials evaluating fentanyl IV as an anaesthetic. These subjects took at least 1 dose of fentanyl IV and provided safety data. Based on pooled safety data from these clinical trials, the most commonly reported (≥5% incidence). Adverse Reactions were (with % incidence): nausea (26.1); vomiting (18.6); muscle rigidity (10.4); hypotension (8.8); hypertension (8.8); bradycardia (6.1); and sedation (5.3).

Including the above-mentioned adverse reactions, the following table displays adverse reactions that have been reported with the use of fentanyl IV from either clinical trials or postmarketing experiences.

The displayed frequency categories use the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available clinical trial data).

Table 1: Adverse Reactions

System Organ Class

Adverse Reactions

Frequency Category

Very Common

(≥ 1/10)

Common

(≥ 1/100 to < 1/10)

Uncommon

(≥ 1/1,000 to < 1/100)

Not Known

Immune System Disorders

Hypersensitivity

(such as anaphylactic shock, anaphylactic reaction, urticaria)

Psychiatric Disorders

Euphoric Mood

Nervous System Disorders

Dyskinesia;

Sedation;

Dizziness

Headache

Convulsions (including clonic convulsions and grand mal convulsion);

Stupor;

Loss of conciousness/Coma;

Myoclonus

Eye Disorders

Visual disturbance

Cardiac Disorders

Bradycardia;

Tachycardia;

Arrhythmia

Cardiac arrest

Vascular Disorders

Hypotension;

Hypertension;

Vein pain

Phlebitis;

Blood pressure fluctuation

Respiratory, Thoracic and Mediastinal Disorders

Laryngospasm;

Bronchospasm;

Apnoea

Hyperventilation;

Hiccups

Respiratory depression

Gastrointestinal Disorders

Nausea;

Vomiting

Skin and Subcutaneous Tissue Disorders

Dermatitis allergic

Pruritus

Musculoskeletal and Connective Tissue Disorders

Muscle rigidity (which may also involve the thoracic muscles)

General Disorders and Administration Site Conditions

Chills;

Hypothermia

Injury, Poisoning and Procedural Complications

Confusion postoperative;

Anaesthetic complication neurological

Airway complication of anaesthesia:

Agitation postoperative;

Procedural complication

When a neuroleptic is used with fentanyl, the following adverse reactions may be observed: chills and/or shivering, restlessness, post-operative hallucinatory episodes and extrapyramidal symptoms (see Section 4.4).

Cases of serotonin syndrome have been reported when products containing fentanyl are administered concomitantly with highly serotonergic drugs (see sections 4.4 and 4.5).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

HPRA Pharmacovigilance

Earlsfort Terrace

IRL-Dublin 2

Tel: +353 1 6764971

Fax: +353 1 6762517

Website: www.hpra.ie

e-mail: medsafety@hpra.ie


Go to top of the page
4.9 Overdose

Symptoms and signs

An overdose of fentanyl manifests itself as an extension of its pharmacologic actions. Respiratory depression which can vary in severity from bradypnoea to apnoea may occur.

Treatment

In the presence of hypoventilation or apnoea, oxygen should be administered and respiration should be assisted or controlled as indicated. A specific opioid antagonist should be used as indicated to control respiratory depression. This does not preclude the use of more immediate countermeasures. The respiratory depression may last longer than the effect of the antagonist; additional doses of the latter may therefore be required.

If depressed respiration is associated with muscular rigidity, an intravenous neuromuscular blocking agent might be required to facilitate assisted or controlled respiration.

The patient should be carefully observed; body warmth and adequate fluid intake should be maintained. If hypotension is severe or if it persists, the possibility of hypovolaemia should be considered and, if present, it should be controlled with appropriate parenteral fluid administration.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Anaesthetic general, opioid anaesthetic, ATC code: N01AH01

Fentanyl is a well established chemical entity. It is an opioid analgesic with a high affinity for the µ-opioid receptor.

Fentanyl can be used as an analgesic supplement to general anaesthesia or as the sole anaesthetic. Fentanyl preserves cardiac stability, and obtunds stress-related hormonal changes at higher doses. A dose of 100 µg (2.0 ml) is approximately equivalent in analgesic activity to 10 mg of morphine. The onset of action is rapid. However, the maximum analgesic and respiratory depressant effect may not be noted for several minutes. The usual duration of action of the analgesic effect is approximately 30 minutes after a single IV dose of up to 100 µg. Depth of analgesia is dose-related and can be adjusted to the pain level of the surgical procedure.

Like other opioid analgesics, fentanyl, depending upon the dose and speed of administration, can cause muscle rigidity, as well as euphoria, miosis and bradycardia.

Histamine assays and skin-wheal testing have indicated that clinically significant histamine release is rare with fentanyl.

All actions of fentanyl are reversed by a specific opioid antagonist.


Go to top of the page
5.2 Pharmacokinetic properties

Fentanyl is a synthetic opioid with µ-agonist pharmacologic effects.

Distribution

After intravenous injection, fentanyl plasma concentrations fall rapidly, with sequential distribution half-lives of about 1 minute and 18 minutes, and a terminal elimination half-life of 475 minutes. Fentanyl has a Vc (volume of distribution of the central compartment) of 13 L, and a total Vdss (distribution volume at steady-state) of 339 L. The plasma-protein binding of fentanyl is about 84%.

Metabolism

Fentanyl is rapidly metabolised, mainly in the liver by CYP3A4. The major metabolite is norfentanyl. Fentanyl clearance is 574 ml/min.

Elimination

Approximately 75% of the administered dose is excreted in the urine within 24 hours and only 10% of the dose eliminated in urine is present as unchanged drug.

Special populations

Paediatrics

The plasma protein binding of fentanyl in newborns is approximately 62% which is lower than in adults. The clearance and the volume of distribution are higher in infants and children. This may result in an increased dose requirement for fentanyl.

Renal impairment

Data obtained from a study administering IV fentanyl in patients undergoing renal transplantation suggest that the clearance of fentanyl may be reduced in this patient population. If patients with renal impairment receive fentanyl, they should be observed carefully for signs of fentanyl toxicity and the dose reduced if necessary (see section 4.2 Posology and method of administration).

Adult patients with burns

An increase in clearance up to 44% together with a larger volume of distribution results in lower fentanyl plasma concentrations. This may require an increased dose of fentanyl.

Obese Patients

An increase in clearance of fentanyl is observed with increased body weight. In patients with a BMI >30, clearance of fentanyl increases by approximately 10% per 10 kg increase of the fat free mass (lean body mass).


Go to top of the page
5.3 Preclinical safety data

Fentanyl has a broad safety margin. In rats, the ratio LD50/ED50 for the lowest level of analgesia is 281.8, as compared with 69.5 and 4.8 for morphine and pethidine respectively.

In vitro fentanyl showed mutagenic effects in a mammalian cell culture assay, only at cytotoxic concentrations and along with metabolic activation. Fentanyl showed no evidence of mutagenicity when tested in in vivo rodent studies and bacterial assays. In a two-year carcinogenicity study conducted in rats, fentanyl was not associated with an increased incidence of tumours at subcutaneous doses up to 33 µg/kg/day in males or 100 µg/kg/day in females, which were the maximum tolerated doses for males and females.

Some tests on female rats showed reduced fertility as well as embryo mortality. These findings were related to maternal toxicity and not a direct effect of the drug on the developing embryo. There was no evidence of teratogenic effects.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipient(s)

Sodium chloride

Water for injections


Go to top of the page
6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.


Go to top of the page
6.3 Shelf life

Unopened: 3 years.

The product should be used immediately after opening.


Go to top of the page
6.4 Special precautions for storage

Do not store above 30°C. Keep ampoules in the outer carton.


Go to top of the page
6.5 Nature and contents of container

Colourless glass ampoules (Ph. Eur., Type I).

Pack size: packs of 10 x 2 ml ampoules, packs of 5 and 10* x 10 ml ampoules.

*Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

Wear gloves while opening ampoule.

Accidental dermal exposure should be treated by rinsing the affected area with water. Avoid usage of soap, alcohol, and other cleaning materials that may cause chemical or physical abrasions to the skin.

For single use only. Discard any unused contents.

See section 4.2.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Janssen-Cilag Ltd

50-100 Holmers Farm Way

High Wycombe

Bucks

HP12 4EG

UK


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PA 748/44/1


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of First Authorisation:

Date of Renewal of Authorisation:

1st April 1978

10th June 2007


Go to top of the page
10. DATE OF REVISION OF THE TEXT

13 June 2017



Link to this document from your website:
http://www.medicines.ie/medicine/2147/SPC/Sublimaze+50+micrograms+ml%2c+Solution+for+Injection/

Document Links

 
  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients

 
   fentanyl citrate